suck pdf from google scholar
PDF vom PMID19086328 :   free
PDF vom PMID19086328
suck pdf from library genesis
English Wikipedia

Nephropedia Template TP (

Twit Text


  • DeepDyve
  • Pubget Overpricing


  • lüll
  • Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer
  • Peeters M; Balfour J; Arnold D
  • Aliment Pharmacol Ther 2008[Aug]; 28 (3): 269-81
  • BACKGROUND: Panitumumab is a fully human monoclonal IgG2 antibody targeting the epidermal growth factor receptor (EGFR). AIM: To review the efficacy of panitumumab in the treatment of metastatic colorectal cancer (mCRC). METHODS: Available literature identified from PubMed and conference websites was reviewed. RESULTS: In phase 2-3 studies, panitumumab monotherapy achieved objective response rates (ORRs) of 8-13% in relapsed/refractory EGFR-expressing mCRC. In a randomized phase 3 study (463 patients), panitumumab almost halved the risk of disease progression/death vs. a control group receiving only best supportive care (hazard ratio 0.54; 95% CI: 0.44-0.66; P < 0.0001). Objective response was achieved in 22/231 (10%) patients randomized to panitumumab--and also in 20/176 (11%) patients assigned to the control group who received panitumumab in a separate crossover protocol after disease progression. Response was confined to patients with tumours harbouring wild-type KRAS (ORR approximately equal to 20%). Panitumumab is also being evaluated in earlier lines of treatment. Panitumumab monotherapy is generally well tolerated; the most common toxicities are skin toxicity (approximately equal to 90%) and diarrhoea (<30%). Development of anti-panitumumab antibodies (0.3% by ELISA) and grade 3-4 infusion reactions (<1%) are rare. CONCLUSION: Panitumumab is an effective monotherapy option for patients with relapsed/refractory EGFR-expressing mCRC harbouring wild-type KRAS.
  • |Adenocarcinoma/*drug therapy/genetics/secondary[MESH]
  • |Antibodies, Monoclonal, Humanized[MESH]
  • |Antibodies, Monoclonal/administration & dosage[MESH]
  • |Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]
  • |Biomarkers, Tumor/genetics[MESH]
  • |Cetuximab[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Colorectal Neoplasms/*drug therapy/genetics/secondary[MESH]
  • |Disease-Free Survival[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Immunoglobulin G/genetics[MESH]
  • |Male[MESH]
  • |Panitumumab[MESH]
  • |Patient Selection[MESH]
  • |Proto-Oncogene Proteins p21(ras)[MESH]
  • |Proto-Oncogene Proteins/administration & dosage[MESH]
  • |ras Proteins/administration & dosage[MESH]





  • *{{pmid19086328}}
    *<b>[http://www.kidney.de/mlpefetch.php?search=19086328 Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer ]</b> Aliment Pharmacol Ther 2008; 28(3) ; 269-81 Peeters M; Balfour J; Arnold D

        *19086328*

    Nephropedia PMID record

    Deutsche Wikipedia - im Artikel

    Hier den unten stehenden Textblock hineinkopieren

    Aliment Pharmacol Ther

    269 3.28 2008